Cargando…

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus

OBJECTIVE: To review the efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists to determine their role in type 2 diabetes mellitus (T2DM). DATA SOURCES: A Medline search was conducted using the keywords exenatide, liraglutide, glucagon-like peptide-1, type 2 diabetes mellitus, hyperglycemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brice, Kira R., Tzefos, Maria K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411513/
https://www.ncbi.nlm.nih.gov/pubmed/22879790
http://dx.doi.org/10.4137/CMED.S4086
_version_ 1782239839621480448
author Brice, Kira R.
Tzefos, Maria K.
author_facet Brice, Kira R.
Tzefos, Maria K.
author_sort Brice, Kira R.
collection PubMed
description OBJECTIVE: To review the efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists to determine their role in type 2 diabetes mellitus (T2DM). DATA SOURCES: A Medline search was conducted using the keywords exenatide, liraglutide, glucagon-like peptide-1, type 2 diabetes mellitus, hyperglycemia, pharmacokinetics, pharmacology and safety. STUDY SELECTION: All identified articles written in English were evaluated with priority given to controlled, randomized trials including human data. References of identified published trials were reviewed for additional trials to be included in the review. DATA SYNTHESIS: Exenatide and liraglutide are GLP-1 agonists approved for the treatment of T2DM. Several randomized, active and placebo controlled trials examining the efficacy and safety of exenatide and liraglutide both as monotherapy and in combination therapy have been conducted. Both agents have demonstrated improved glycemic control in addition to weight loss and increased beta-cell function. The most common adverse effects are gastrointestinal in nature and appear to be transient. CONCLUSION: It appears exenatide and liraglutide are safe and effective in the treatment of T2DM and may exhibit effects that make them preferred over other anti-diabetic medications.
format Online
Article
Text
id pubmed-3411513
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-34115132012-08-09 The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus Brice, Kira R. Tzefos, Maria K. Clin Med Insights Endocrinol Diabetes Review OBJECTIVE: To review the efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists to determine their role in type 2 diabetes mellitus (T2DM). DATA SOURCES: A Medline search was conducted using the keywords exenatide, liraglutide, glucagon-like peptide-1, type 2 diabetes mellitus, hyperglycemia, pharmacokinetics, pharmacology and safety. STUDY SELECTION: All identified articles written in English were evaluated with priority given to controlled, randomized trials including human data. References of identified published trials were reviewed for additional trials to be included in the review. DATA SYNTHESIS: Exenatide and liraglutide are GLP-1 agonists approved for the treatment of T2DM. Several randomized, active and placebo controlled trials examining the efficacy and safety of exenatide and liraglutide both as monotherapy and in combination therapy have been conducted. Both agents have demonstrated improved glycemic control in addition to weight loss and increased beta-cell function. The most common adverse effects are gastrointestinal in nature and appear to be transient. CONCLUSION: It appears exenatide and liraglutide are safe and effective in the treatment of T2DM and may exhibit effects that make them preferred over other anti-diabetic medications. Libertas Academica 2011-03-14 /pmc/articles/PMC3411513/ /pubmed/22879790 http://dx.doi.org/10.4137/CMED.S4086 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Brice, Kira R.
Tzefos, Maria K.
The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
title The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
title_full The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
title_fullStr The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
title_full_unstemmed The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
title_short The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
title_sort clinical efficacy and safety of glucagon-like peptide-1 (glp-1) agonists in adults with type 2 diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411513/
https://www.ncbi.nlm.nih.gov/pubmed/22879790
http://dx.doi.org/10.4137/CMED.S4086
work_keys_str_mv AT bricekirar theclinicalefficacyandsafetyofglucagonlikepeptide1glp1agonistsinadultswithtype2diabetesmellitus
AT tzefosmariak theclinicalefficacyandsafetyofglucagonlikepeptide1glp1agonistsinadultswithtype2diabetesmellitus
AT bricekirar clinicalefficacyandsafetyofglucagonlikepeptide1glp1agonistsinadultswithtype2diabetesmellitus
AT tzefosmariak clinicalefficacyandsafetyofglucagonlikepeptide1glp1agonistsinadultswithtype2diabetesmellitus